SciELO - Scientific Electronic Library Online

 
vol.5 número3Aurícula derecha: un buen aliado en la estimulación ventricular izquierda durante el implante percutáneo de válvula aórtica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


REC: Interventional Cardiology

versión On-line ISSN 2604-7276versión impresa ISSN 2604-7306

Resumen

GARCIA-GUIMARAES, Marcos et al. Paravalvular leak with ACURATE neo and neo2: a comparative study with calcium quantification. REC Interv Cardiol ES [online]. 2023, vol.5, n.3, pp.170-177.  Epub 29-Ene-2024. ISSN 2604-7276.  https://dx.doi.org/10.24875/recic.m23000369.

Introduction and objectives:

Moderate or severe paravalvular leak (PVL) following transcatheter aortic valve implantation (TAVI) has been associated with worse outcomes. Aortic valve (AV) calcification is a strong predictor of PVL. ACURATE neo (Boston Scientific Corporation, United States) is a self-expanding transcatheter heart valve to treat degenerative aortic stenosis. We evaluated PVL after ACURATE neo and neo2 implantation, and the role of AV calcification.

Methods:

We analyzed patients referred for TAVI with ACURATE neo and neo2 from a large volume tertiary center. All cardiac computed tomography scans were analyzed using 3Mensio Structural Heart software (Pie Medical Imaging, The Netherlands). The volume of AV calcium was quantified using contrast-enhanced cardiac computed tomography series. The 30-day clinical and echocardiographic data were prospectively recorded.

Results:

We included 165 patients referred for TAVI with ACURATE (neo = 87; neo2 = 78). Median age was 82 years-old, 65% were women with a median EuroSCORE II of 4.7 [IQR, 2.4-6.1]. Patients in the neo group showed a larger amount of total AV calcium (320 mm3 vs 200 mm3; P =.0305). We found no significant inter-group differences regarding clinical outcomes both in-hospital or at 30-days. At 30-days, the rate of PVL ≥ mild (61% vs 34%; P <.001) and ≥ moderate (15.9% vs 5.4%; P =.0365) were higher in the neo group. After propensity score matching adjusted by the total amount of AV calcium, neo2 was associated with a lower risk of PVL ≥ mild (OR, 0.35, 95%CI, 0.18-0.69; P =.003), and ≥ moderate (OR, 0.16; 95%CI, 0.03-0.74; P =.019).

Conclusions:

TAVI with ACURATE neo2 vs neo is associated with a lower risk of any degree of PVL and a reduced risk of PVL ≥ moderate. After adjusting for AV calcium volume, ACURATE neo2 was still associated with a lower risk of PVL.

Palabras clave : Transcatheter aortic valve implantation; Transcatheter heart valve; Paravalvular leak.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )